Pre-made Solitomab benchmark antibody ( Bispecific scFv, anti-EPCAM;CD3E therapeutic antibody, Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-528
Pre-Made Solitomab biosimilar, Bispecific scFv, Anti-EPCAM;CD3E Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Solitomab (INN; development code MT110) is an artificial bispecific monoclonal antibody that is being investigated as an anti-cancer drug. It is a fusion protein consisting of two single-chain variable fragments (scFvs) of different antibodies on a single peptide chain of about 55 kilodaltons. One of the scFvs binds to T cells via the CD3 receptor, and the other to EpCAM as a tumor antigen against gastrointestinal, lung, and other cancers.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Solitomab biosimilar, Bispecific scFv, Anti-EPCAM;CD3E Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1;T3E/TCRE/IMD18 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Discontinued||Solid tumours|
Case Study -- GeneMedi's GMP-Bios-ab-528 (Pre-Made Solitomab biosimilar) is validated to bind the Jurkat cells by Flow Cytometry (FACS Analysis)
GM R&D department tested the binding ability of GeneMedi's GMP-Bios-ab-528 (Pre-Made Solitomab biosimilar) to the Jurkat cells by Flow Cytometry. Below is the conclusion:
1.Good binding of GM-528 to Jurkat cells.
2.High concentration (10ug/ml) of GM-528 should be used for CD3 detection.
3.The CD3 antibody is derived from L2K. The affinity of L2K is about 35 times lower than OKT3. (Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3. Cancer Res. 2008)
Figure 1. GeneMedi's GMP-Bios-ab-528 (Pre-Made Solitomab biosimilar) is validated to bind the Jurkat cells by Flow Cytometry (FACS Analysis).
- 6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Email: [email protected]